FocalTherics (NASDAQ:FOCL) General Counsel Sanket Shah Purchases 5,000 Shares

Posted by Geri Gentry on Aug 18th, 2026

FocalTherics (NASDAQ:FOCL – Get Free Report) General Counsel Sanket Shah bought 5,000 shares of FocalTherics stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $4.75 per share, with a total value of $23,750.00. Following the acquisition, the general counsel directly owned 72,500 shares in the company, valued at approximately $344,375. This represents a 7.41% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

FocalTherics Stock Down 8.4%

Shares of FOCL opened at $4.36 on Tuesday. FocalTherics has a twelve month low of $1.30 and a twelve month high of $6.40. The company has a market capitalization of $163.41 million, a PE ratio of -4.23 and a beta of -0.04. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. The firm’s 50-day moving average is $5.38.

FocalTherics (NASDAQ:FOCL – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The firm had revenue of $13.20 million during the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. Analysts expect that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On FocalTherics

A number of hedge funds and other institutional investors have recently bought and sold shares of FOCL. Flax Pond Capital LLC purchased a new position in FocalTherics in the 4th quarter worth approximately $2,623,000. Leonteq Securities AG purchased a new stake in shares of FocalTherics during the 4th quarter valued at $313,000. Rock Springs Capital Management LP lifted its holdings in shares of FocalTherics by 7.1% during the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after acquiring an additional 91,500 shares during the last quarter. Kovack Advisors Inc. bought a new stake in shares of FocalTherics during the 4th quarter worth $53,000. Finally, Lido Advisors LLC purchased a new position in FocalTherics in the first quarter worth $40,000. Hedge funds and other institutional investors own 62.74% of the company’s stock.

Analysts Set New Price Targets

FOCL has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research report on Tuesday, June 2nd. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday. Piper Sandler restated a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research report on Friday. Finally, Mizuho set a $15.00 target price on FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.75.

View Our Latest Stock Analysis on FocalTherics

FocalTherics News Summary

Here are the key news stories impacting FocalTherics this week:

Positive Sentiment: Company insiders collectively purchased 116,000 shares at $4.75 per share, representing approximately $551,000 of open-market buying. The purchases included CEO Ryan Rhodes, CFO Kenneth S. Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and Directors Lance Willsey, Joshua Levine, Fran Schulz, and David R. Horn. The coordinated buying may suggest that management and directors view the recent weakness as an attractive entry point. FocalTherics insider transaction filing
Positive Sentiment: Director Lance Willsey made the largest purchase, acquiring 50,000 shares for $237,500. CEO Ryan Rhodes also bought 21,000 shares for $99,750, while several other executives and directors increased their holdings by between 2.83% and 196.08%. FocalTherics director transaction filing
Negative Sentiment: FocalTherics recently reported quarterly earnings of a $0.39-per-share loss, missing the consensus estimate for a $0.20 loss by $0.19. Revenue was $13.20 million, while the company posted a negative net margin of 56.26% and negative return on equity of 175.45%. Analysts expect a full-year loss of approximately $0.78 per share, which remains a key risk for the stock.

About FocalTherics

(Get Free Report)

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.